CK Life Sciences devoting resources toward high-potential R&D

A single successful biotech product could be worth more than many listed infrastructure or property firms, according to CK Life Sciences International (0775).

Speaking at the company's annual general meeting, chairman Victor Li Tzar-kuoi said biotech is a high-risk, high-reward sector.

He noted that infrastructure or rental stocks might be more suitable for dividend income investment, while a well-rounded portfolio allocating part of capital to high-potential investment is the right approach.

Li said the group is evaluating strategic options, including potential listings or asset sales, but will allocate capital with discipline to support research and development.

STAFF REPORTER